In Treatment for Muscle Invasive Bladder Cancer

Choosing neoadjuvant chemo for muscle-invasive bladder cancer? Compare ddMVAC and Gemcitabine-Cisplatin outcomes, side effects, and survival rates for 2026.

Facing muscle-invasive bladder cancer? Learn the differences between cystectomy and chemoradiation to help you make an informed decision about your treatment.

Considering bladder preservation? Learn if you qualify for trimodality therapy (TMT) as an effective alternative to radical cystectomy for muscle-invasive cancer.

Facing an MIBC diagnosis? Learn why personalized data is essential for comparing radical cystectomy vs. bladder preservation and choosing the best treatment path.

Navigating muscle-invasive bladder cancer treatment? Explore the pros and cons of radical cystectomy versus bladder preservation to make an informed decision.

If doctors are treating you for muscle-invasive bladder cancer (MIBC), your treatment plan may include pembrolizumab (P) in combination with enfortumab vedotin-ejfv (EV). In July 2026, the U.S. Food and Drug Administration (FDA) expanded its approval of this combination as treatment before surgery, followed by treatment after bladder removal surgery, to include people with MIBC […]

A diagnosis of muscle-invasive bladder cancer (MIBC) sets a lot in motion quickly. As a patient, you’ll be immersed in imaging scans, staging conversations, and a treatment timeline that typically leads toward chemotherapy and a major surgery called radical cystectomy. In the middle of that whirlwind, one of the most useful things a patient can […]

Discover why neoadjuvant chemotherapy before radical cystectomy is the gold standard for muscle-invasive bladder cancer to improve survival and treatment outcomes.

Take control of your MIBC journey. Learn the essential questions to ask your care team about treatment options, surgery, and clinical trials for bladder cancer.

For people with high-risk muscle-invasive urothelial carcinoma, including bladder cancer, treatment doesn’t always end after surgery. Even after the bladder and surrounding tissue are removed, there’s still a risk that cancer can come back. That’s why some patients receive adjuvant therapy, treatment given after surgery to lower the risk of recurrence. The AMBASSADOR trial found […]

On July 10th, 2026, the U.S. Food and Drug Administration (FDA) approved pembrolizumab (Keytruda) in combination with enfortumab vedotin (Padcev) for use both before and after bladder removal surgery (radical cystectomy) in adults with muscle-invasive bladder cancer (MIBC). The approval is significant for two reasons: it introduces a treatment strategy that spans both the neoadjuvant […]

The U.S. Food and Drug Administration (FDA) has approved atezolizumab (Tecentriq) and atezolizumab and hyaluronidase-tqjs (Tecentriq Hybreza) for certain patients with muscle-invasive bladder cancer (MIBC) after bladder removal surgery (cystectomy). The FDA also approved Signatera CDx as the companion diagnostic test used to identify eligible patients. This approval marks an important step toward more personalized […]